Global Contraceptives Market is Projected to Reach a Value of US$ 37,242.7 by 2025-end



The global contraceptives market is projected to reach a value of US$ 37,242.7 by 2025-end, expanding at a CAGR of 6.4%.

Press Release

Amazon Music Disney Promo

Prevalence of unwanted pregnancies has necessitated the need to seek more effective contraceptive treatment. A majority of these pregnancies occur among adolescents and young women and are the principal source of the spread of sexually transmitted infections. These include HIV, chlamydia, genital herpes and hepatitis B. Concerned by this, governments across the world have heavily invested in sexual education programs in order to acquaint people to the dangers of such diseases.

For detailed insights on enhancing your product footprint, request for a sample here –

Propelled by these abovementioned factors, the global contraceptives market is set to expand positively during the forecast period (2020-2025). The global contraceptives market is projected to reach a value of US$ 37,242.7 by 2025-end, expanding at a CAGR of 6.4%. Other developments such as introduction of innovative devices is also expected to boost market growth for contraceptives.

Mandatory social distancing amid the COVID-19 pandemic, however, is anticipated to generate tremors in the global contraceptives market supply chain, owing to limited production capacity due to less employee strength and avoidance of physical contact among adults.

Key Takeaways of Global Contraceptives Market Study

  • Contraceptive devices shall capture the maximum market share of the global contraceptives market (>50%). This is attributed to the major side effects of ingesting contraceptive drugs, such as nausea, headache, weight gain, increased bleeding, dysmenorrhea and menstrual changes, among women. The introduction of custom-fit condoms by key market players is equally expected to boost market share. Anticipated CAGR for the forecast period is pegged at 6.6%.
  • Hospitals shall account for the maximum distribution of contraceptive devices among patients. Favorable reimbursement policies to hospitals is a key driver behind the growth of this segment. Projections indicate a market share of one-third during the forecast period.
  • North America shall dominate the global contraceptives market, due to increased incidences of unwanted pregnancies and burgeoning demand for reversible contraceptives among the patients. The region is expected to surpass a valuation of US$ 12.9 Bn growing at a CAGR of 6.6% during the forecast period.

For critical insights on this market, request for methodology here –

  • Asia-Pacific shows high potential for growth of the global contraceptives market. The region shows staggering prospects, with a CAGR pegged at 6.8% throughout the forecast period.
  • The COVID-19 pandemic is anticipated to initiate a decline in the sales of contraceptives globally. This is attributed to social distancing among young adults in order to contain the spread of the virus. This includes refrainment from any kind of physical contact, including sexual intercourse.
  • Supply-chain disruptions are anticipated, attributed to limited production capacity of manufacturing plants. Condoms, the most popular contraceptive, are anticipated to register significant downturn in production. The Asian market is poised to experience the maximum shortage as most condoms are produced in China and Indonesia.
  • Fortunately, healthcare practitioners and key manufacturers are taking proactive measures to ensure minimum supply-chain disruptions to the global contraceptives market. To that end, the UN Population Fund (UNFPA) has urged governments across the world to encourage public and private partnerships to mobilize the private sector and enhance the supplies of sanitary items, medical equipment and antiretroviral drugs. The fund also calls for appropriate administration and in-country distribution of required sexual and reproductive health (SRH) products and unceasing investment in strengthening the reproductive and sexual health supply chain.

Global Contraceptives Market Segmentation

Fact.MR has studied the global contraceptives market with detailed segmentation on the basis product type, distribution channel and key regions.

Product Type

  • Contraceptive drugs (hormonal):
  • Oral Contraceptives:
    • Combined Contraceptives
    • Mini pills
    • Contraceptive Injectable
    • Topical Contraceptive Patch
  • Contraceptive Devices:
  • Male Contraceptive Devices
  • Female Contraceptive Devices:
    • Female Condoms
    • Contraceptive Diaphragms
    • Contraceptive Sponges
    • Contraceptive Vaginal Rings
    • Intrauterine Devices
    • Sub-dermal Contraceptive Implants
    • Non-surgical Permanent Contraception Devices

Distribution Channel

  • Hospital Pharmacy:
    • Public
    • Private
  • Independent Pharmacy
  • Online Platform
  • Clinics
  • Others

Key Regions

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

“The global contraceptives market is expected to be leveraged significantly in the future, driven by accelerating instances of sexually transmitted infections. This has encouraged key market players to invest in research and development of effective contraceptive techniques. This shall be a significant growth driver,” concludes a Fact.MR analyst.

For in-depth competitive analysis, buy now –

Global Contraceptives Market: Competitive Landscape 

With a highly fragmented market, several important players dominate the contraceptives market. Some of the key market players are: Allergen, plc, Pfizer, Inc, Teva Pharmaceutical Industries Ltd., Bayer AG and Janssen Pharmaceutical Company. The companies primarily concentrate on product launches in order to broaden their market footprint. Pfizer Inc, for instance, manufactures Sayana Press, an injectable contraceptive for women available in the U.K. The company is also in the process of conducting a study evaluating levonorgestrel and ethinyl estradiol as potential oral contraceptives.

Merck & Co, Inc., offers contraceptive care in the form of combined oral pills, vaginal rings, intrauterine devices and sub-dermal implants. Popular products include Cyclessa, Desogen, NuvaRing, Implanon and Nexplanon. Another important player, Cipla, manufactures oral contraceptives named Crisanta. The medicine contains Drospirenone which prevents the fertilization of the egg with the sperm. It also induces hormonal changes contributing to the prevention of pregnancy.

Read More Trending and Similar Reports from Fact.MR –

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: [email protected]
Visit Our Website: